Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

References

• Cardiovascular diseases (CVDs). Fact sheet No.317. Sep 2009GenevaWorld Health Organization2009
   Google Scholar
• American Heart AssociationCardiovascular Disease Statistics2010 Available from: http://www.americanheart.org/presenter.jhtml?identifier=4478. Accessed May 20, 2010.
   Google Scholar
• WilsonPWFD’AgostinoRBLevyDPrediction of coronary heart disease using risk factor categoriesCirculation199897183718479603539
   PubMed Web of Science ®Google Scholar
• WikipediaAtherosclerosis Available from: http://en.wikipedia.org/wiki/Atherosclerosis. Accessed May 20, 2010.
   Google Scholar
• LibbyPInflammation and the Pathogenesis of Atherothrombotic Disease Available from: http://www.lipidsonline.org/slides/slide01.cfm?tk=20&pg=1. Accessed May 20, 2010.
   Google Scholar
• National Cholesterol Education ProgramThird report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adultsBethesda, MDNational Heart, Lung, and Blood Institute2002
   Google Scholar
• GrundyScott MSmall LDL, Atherogenic dyslipidemia, and metabolic syndromeCirculation199795148994405
   PubMed Web of Science ®Google Scholar
• PetersALClinical relevance of non-HDL cholesterol in patients with diabetesClin Diabetes20082637
   Google Scholar
• KannelWilliam BMcGeeDLDiabetes and cardiovascular disease: A Framingham studyJAMA197924120352038430798
   PubMed Web of Science ®Google Scholar
• World Health OrganizationDiabetes Programme: Country and regional data Available from: http://www.who.int/diabetes/facts/world_figures/en/. Accessed May 20, 2010.
   Google Scholar
• World Health OrganizationDiabetes Programme: WHO region of the Americas Available from: http://www.who.int/diabetes/facts/world_figures/en/index3.html. Accessed on May 20, 2010.
   Google Scholar
• National Diabetes Fact Sheet: General information and national estimates on diabetes in the United States, 2007 US Department of Health and Human Services: Centers for Disease Control and Prevention2008
   Google Scholar
• HuangESBasuAO’GradyMCaprettaJCProjecting the future of diabetes population size and related costs for the USDiabetes Care2009322225222919940225
   PubMed Web of Science ®Google Scholar
• HaffnerSMAlexanderCMCookTJReduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival StudyArch Intern Med19991592661266710597756
   PubMed Web of Science ®Google Scholar
• GoldbergRBMelliesMJSacksFMCardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analysis in the cholesterol and recurrent events (CARE) trial: The CARE InvestigatorsCirculation199898251325199843456
   PubMed Web of Science ®Google Scholar
• Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med1998339134913579841303
   PubMedGoogle Scholar
• CollinsRArmitageJParishSSleighPPetoRHeart Protection Study Collaborative GroupMCR/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomized placebo-controlled trialLancet20033612005201612814710
   PubMedGoogle Scholar
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT)JAMA20022882998300712479764
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRfor the ASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive subjects who have average or lower-than-average cholesterol concentratons, in the Anglo-Scandinavian Cardiac Outcome Trial – Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNThe ALLHAT officers and coordinators for the ALLHAT Collaborative Research GroupPrimary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trialLancet200436468569615325833
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of Medical Care in Diabetes – 2009Diabetes Care200932Suppl 1S13S6119118286
   PubMed Web of Science ®Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology FoundationDiabetes Care20083181182218375431
   PubMed Web of Science ®Google Scholar
• GrundySMLow-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapyCirculation20021062526252912427645
   PubMed Web of Science ®Google Scholar
• KennedyAGMacLeanCDLittenbergBThe challenge of achieving national cholesterol goals in patients with diabetesDiabetes Care2005281029103415855562
   PubMed Web of Science ®Google Scholar
• NestoRWLDL cholesterol lowering in Type 2 diabetes: What is the optimum approachClin Diabetes20082616
   Google Scholar
• StaelsBFruchartJ-CTherapeutic roles of peroxisome proliferator-activated receptor agonistsDiabetes2005542460247016046315
   PubMed Web of Science ®Google Scholar
• Vu-DacNSchoonjansKKosykhVFibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptorJ Clin Invest1995967417507635967
   PubMed Web of Science ®Google Scholar
• VamecqJLatruffeNMedical significance of peroxisome proliferator-activated receptorsLancet199935414114810408502
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKEffects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hyper-cholesterolemia. Two randomized controlled trialsJAMA20072971362137317384435
   PubMed Web of Science ®Google Scholar
• YamauchiTKamonJWakiHThe fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesityNat Med2001794194611479627
   PubMed Web of Science ®Google Scholar
• HardieGDCarlingDCarlsonMThe AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cellAnnu Rev Biochem1998678218559759505
   PubMed Web of Science ®Google Scholar
• FryerLGDParbu-PatelACarlingDThe anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathwaysJ Biol Chem2002277252262523211994296
   PubMed Web of Science ®Google Scholar
• LincoffMAWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patient with type 2 diabetes mellitus. A meta-analysis of randomized trialsJAMA20072981180118817848652
   PubMed Web of Science ®Google Scholar
• The BARI 2D Study GroupRandomized trial of therapies for Type 2 diabetes and coronary artery diseaseN Engl J Med20093602503251519502645
   PubMed Web of Science ®Google Scholar
• PetersAAClinical relevance of non-HDL cholesterol in patients with diabetesClin Diabetes20082637
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysisLancet200837111712518191683
   PubMed Web of Science ®Google Scholar
• The FIELD Study InvestigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trialLancet20053661849186116310551
   PubMed Web of Science ®Google Scholar